Knowing whether a patient’s tumor has a wild-type or mutated KRAS gene may help plan cancer treatment. A term used to describe a gene called KRAS when it is found in its natural, non-mutated (unchanged) form. The KRAS gene makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death.

In the Phase III CRYSTAL study, published in 2009, patients with the wild-type KRAS gene treated with Erbitux plus chemotherapy showed a response rate of up to 59% compared to those treated with chemotherapy alone.

Wild type RAS plays critical roles in both RAS mutant and RAS wild type cancers, in a context-dependent manner. The wild type KRAS isoform largely acts as a tumour suppressor in the context of the cognate mutant KRAS isoform, and its loss facilitates initation and progression as well as metastasis.

If your KRAS biomarker result is reported as “KRAS wild-type” or “KRAS WT” this means there is no KRAS mutation in your cancer. If there is a KRAS mutation in your cancer, it will be reported as “KRAS mutant” or its specific mutation will be listed, for example “KRAS G12C” or “KRAS G12V”.

2021年11月15日 · Compared with wild-type KRAS cells, mutant KRAS-driven tumour cells may be more dependent on certain genes that are necessary for the maintenance of the KRAS-driven cellular state.

1 天前 · The normal form of the gene is called wild-type KRAS, while mutated forms have been found in cancers such as non-small cell lung, colorectal and pancreatic cancer. These mutations can cause cancer cells to grow and spread throughout the body. Identifying whether a tumor has a wild-type or mutated KRAS gene is important for planning treatment ...

2016年8月10日 · Major databases were searched to identify RCTs investigating wild-type KRAS mCRC after the first-line treatment, and treatment with FOLFOX/FORFIRI ± cetuximab was compared. Data on clinical efficacy and safety were pooled and compared by …

Our findings suggest that wild-type NRas and KRas differentially affect key features of transformation in MEFs, such as adhesion, cell migration, and the actin cytoskeleton. Selective knockdown of Ras effectors rescues transformation of ras isoform-deficient MEFs.

In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS-wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers in these tumors, which holds the key to unlocking a realm of targeted therapies for patients with this under-studied ...

2020年10月28日 · Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases.The genetic landscape of KRAS wild type PDAC can be divided into three categories.